Rafferty Asset Management, LLC 2seventy Bio, Inc. Transaction History

Rafferty Asset Management, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 11, 2023	BUY	$8.45 - $12.48 $75,771 - $111,908	8,967 Added 4.04%	230,938 $2.34 Million
Q1 2023 May 11, 2023	BUY	$9.21 - $14.98 $832,491 - $1.35 Million	90,390 Added 68.7%	221,971 $2.26 Million
Q4 2022 Feb 13, 2023	BUY	$8.57 - $17.0 $17,808 - $35,326	2,078 Added 1.6%	131,581 $1.23 Million
Q3 2022 Nov 14, 2022	BUY	$12.56 - $17.54 $535,470 - $747,782	42,633 Added 49.08%	129,503 $1.88 Million
Q2 2022 Aug 12, 2022	SELL	$10.55 - $18.81 $1.4 Million - $2.5 Million	-133,030 Reduced 60.5%	86,870 $1.15 Million
Q1 2022 May 13, 2022	BUY	$11.67 - $26.72 $456,542 - $1.05 Million	39,121 Added 21.64%	219,900 $3.75 Million
Q4 2021 Feb 10, 2022	BUY	$13.77 - $42.56 $2.49 Million - $7.69 Million	180,779 New	180,779 $4.63 Million

126

45.6M

122K

19.8K

Ticker TSVT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 37,873,600
Market Cap $137M
Description
2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. Its products pipeline includes idecabtagene vicleucel; ide-cel or Abecma and bb21217; and CAR-T cell product candidates for the treatment of multiple myeloma. 2seventy bio, Inc. has a col...

Get notified when there are updates to the investment portfolio of Rafferty Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Rafferty Asset Management, LLC with notifications on news.